Skip to main content
. 2013 Jan 18;12:20. doi: 10.1186/1475-2840-12-20

Table 2.

Multivariable logistic regression analyses

 
NSCS
CBVD
CAD
PAD
PVD
  OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Gender (male)
1.03
0.54–1.96
0.94
1.35
0.70–2.61
0.37
1.53
0.85–2.74
0.16
2.90
1.37–6.12
0.005
2.39
1.53–3.73
0.0001
Age
1.03
1.0–1.06
0.09
1.10
1.06–1.14
<0.0001
1.02
0.99–1.04
0.28
1.09
1.05–1.14
<0.0001
1.11
1.08–1.14
<0.0001
WC
0.99
0.97–1.01
0.36
0.97
0.95–0.99
0.01
0.99
0.98–1.01
0.45
0.98
0.96–1.00
0.07
0.99
0.97–1.00
0.04
Diabetes duration
0.98
0.94–1.01
0.17
0.99
0.96–1.02
0.68
1.01
0.98–1.04
0.60
1.05
1.02–1.08
0.004
1.04
1.02–1.06
0.0001
Smoking History (yes)
1.81
0.52–6.38
0.35
1.44
0.35–5.9
0.62
0.70
0.26–1–90
0.49
2.02
0.63–6.43
0.24
0.85
0.42–1.73
0.65
SBP
1.02
0.99–1.04
0.18
1.01
0.98–1.03
0.46
0.97
0.94–0.99
0.007
1.03
1.01–1.06
0.01
0.99
0.98–1.01
0.73
DBP
0.98
0.94–1.02
0.41
0.99
0.95–1.04
0.84
1.05
1.01–1.10
0.009
0.95
0.91–0.99
0.03
1.01
0.98–1.04
0.75
AH user (yes)
0.96
0.45–2.02
0.91
1.25
0.53–2.94
0.61
2.93
1.19–7.23
0.02
8.4
1.02–68.4
0.04
1,55
0.83–2.89
0.17
HDL-C
0.99
0.97–1.02
0.66
0.99
0.97–1.02
0.74
0.97
0.95–0.99
0.03
0.97
0.95–1.00
0.06
0.98
0.97–0.99
0.03
LDL-C
1.00
0.99–1.01
0.16
1.00
0.99–1.01
0.41
0.99
0.98–0.99
0.02
1.00
0.99–1.01
0.66
1.00
0.99–1.00
0.09
Triglycerides
1.00
0.99–1.00
0.45
0.99
0.99–1.00
0.18
1.00
0.99–1.00
0.70
1.00
0.99–1.01
0.65
1.00
0.99–1.00
0.48
Statin users (yes)
1.51
0.80–2.85
0.21
4.11
1.94–8.60
0.0002
2.31
1.24–4.30
0.009
4.92
1.99–12.10
0.0006
3.42
2.13–5.47
<0.0001
HbA1c
0.94
0.76–1.15
0.53
1.08
0.87–1.34
0.48
0.93
0.76–1.13
0.45
0.78
0.60–1.03
0.09
0.98
0.84–1.13
0.75
FPG
1.00
0.99–1.01
0.26
0.99
0.99–1.00
0.35
1.00
0.99–1.01
0.33
1.00
1.00–1.01
0.51
1.00
0.99–1.00
0.95
MetS (yes) 1.29 0.47–3.57 0.62 1.33 0.43–4.12 0.62 1.10 0.37–3.27 0.86 1.81 0.34–9.73 0.49 2.30 1.01–5.29 0.04

Relationship (ORs) among selected variables and the macro-vascular groups (Dependent variable, macrovascular groups; reference group, NMCV). Values in bold are significant.